Taking a pill half an hour before sex to temporarily prevent pregnancy sounds like a real change in how contraception works. New research from Weill Cornell Medicine in the United States brings that idea a little closer. Scientists are developing an experimental, on-demand male contraceptive that briefly stops sperm from moving. Still, the pill is in early development, and a lot has to be proven before anyone can call it safe and effective for everyday use.
As a gynaecologist, I find it raises a bigger question: could responsibility for contraception become more evenly shared between men and women?
How could a male contraceptive pill work?
Most contraceptive pills prescribed to women work by preventing ovulation through changes in hormonal signals. This experimental male pill takes a different route. It targets how sperm function instead of stopping their production.
The research centres on an enzyme called soluble adenylyl cyclase (sAC), which sperm need in order to swim. When the drug blocks this enzyme, sperm are temporarily immobilised, so they cannot travel through the female reproductive tract to fertilise an egg. In preclinical studies on mice, this approach prevented pregnancy, and the effect faded with time.
The pill is meant to be taken about 30 minutes before sex and may give roughly six to eight hours of protection. It is important to remember that this is the proposed use of an experimental medicine, not a proven guarantee against pregnancy in humans.
Does it stop sperm production or affect future fertility?
There is a key difference between stopping sperm production and temporarily affecting sperm movement. The approach under development at Weill Cornell aims at the second. It is not meant to shut down sperm production in the testes for good.
So a man’s reproductive system would not necessarily go through the kind of changes seen with permanent sterilisation. The effect is intended to be temporary: sperm may still be made, but they cannot swim properly while the medicine is active. Fertility is expected to return as the drug wears off, although proper safety studies must confirm this.
For a gynaecologist, reversibility would be a central concern. A contraceptive meant for occasional use has to show not only that it prevents fertilisation, but also that sperm function returns to normal reliably after every dose.
What must scientists prove before the pill reaches pharmacies?
The first requirement is safety. Unlike medicines that treat an illness, contraceptives are used by otherwise healthy people, sometimes for many years. Researchers need to find out whether repeated use affects the liver, kidneys, cardiovascular system, sexual function or any other part of health.
Second, scientists have to show that it works in humans. Preventing pregnancy in animals does not tell us how dependable the medicine will be for real couples. Clinical trials must establish the actual pregnancy rate, how long protection lasts, the right dose, and whether differences in how people absorb the drug change its performance.
Third, researchers must prove reversibility. They need to confirm that sperm motility recovers consistently and that repeated use leaves no lasting effects on reproduction. Side effects, interactions with other medicines, and what happens after an accidental or incorrect dose also need to be studied.
The research team announced in October 2026 that additional funding would support toxicology and safety studies ahead of a first human trial. The pill is not yet an approved contraceptive.
Could this change the burden of contraception for women?
Women already have several options, including hormonal pills, implants and intrauterine devices. These methods can cause side effects, though, and finding the right one often takes medical advice and some trial and adjustment. Not every woman has problems, and hormonal contraception can bring important benefits beyond preventing pregnancy.
An effective male contraceptive would give couples one more choice, especially when a woman cannot tolerate certain methods or simply prefers not to use them. It might also encourage men to take a more active part in family planning rather than leaving it mostly to their partners.
Even so, a male contraceptive would not solve every reproductive health concern. It would not protect against sexually transmitted infections, so condoms would still matter for preventing infection. Couples would also need open communication and confidence that the method is used consistently.
In the end, the promise of a 30-minute male contraceptive is about more than convenience. It lies in the chance to share responsibility more fairly. Before that can happen, scientists must show that the pill is safe, reliably effective and truly reversible in humans.
The author is the director of obstetrics & gynaecology and director of academics, robotic gynaecology, at CK Birla Hospital, Gurugram.
The opinions expressed in this article are those of the author and do not purport to reflect the opinions or views of THE WEEK.
